Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • EHA 2025

European Hematology Association

June 12 - 15, 2025

  1. All
  2. Acalabrutinib
  3. AZD0120
  4. Surovatamig (AZD0486)

PDF

Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial

PDF

Venetoclax-acalabrutinib for CLL patients relapsing after venetoclax-antiCD20 treatment: Highly effective and low toxicity. Interim analysis of HOVON 159/REVEAL phase 2 trial

PDF

Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the phase 3 ECHO trial

PDF

Measurable residual disease kinetics with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia: Data from the phase 3 AMPLIFY trial

PDF

Analysis of COVID-19 infections with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia in the phase 3 AMPLIFY trial

PDF

Real-world treatment patterns and outcomes among patients with treatment-naïve mantle cell lymphoma in the UK, Sweden, and France

PDF

Real-world treatment patterns and outcomes among patients with high-risk, treatment-naïve mantle cell lymphoma in the UK, Sweden, and France

PDF

Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

PDF

Autologous B cell maturation antigen (BCMA) and CD19 dual targeting FasTCAR-T cells (GC012F/AZD0120) as first-line therapy for elderly patients with newly diagnosed multiple myeloma patients

PDF

Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: Early results from the phase 1/2 SYRUS study

PDF

Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma

PDF

Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial

PDF

Venetoclax-acalabrutinib for CLL patients relapsing after venetoclax-antiCD20 treatment: Highly effective and low toxicity. Interim analysis of HOVON 159/REVEAL phase 2 trial

PDF

Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the phase 3 ECHO trial

PDF

Measurable residual disease kinetics with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia: Data from the phase 3 AMPLIFY trial

PDF

Analysis of COVID-19 infections with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia in the phase 3 AMPLIFY trial

PDF

Real-world treatment patterns and outcomes among patients with treatment-naïve mantle cell lymphoma in the UK, Sweden, and France

PDF

Real-world treatment patterns and outcomes among patients with high-risk, treatment-naïve mantle cell lymphoma in the UK, Sweden, and France

PDF

Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

PDF

Autologous B cell maturation antigen (BCMA) and CD19 dual targeting FasTCAR-T cells (GC012F/AZD0120) as first-line therapy for elderly patients with newly diagnosed multiple myeloma patients

PDF

Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: Early results from the phase 1/2 SYRUS study

PDF

Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States